Quick Answer
UNITED THERAPEUTICS Corp reported Cash and Equivalents of $1.56 billion for fiscal year 2025.
UNITED THERAPEUTICS Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.56B | -8.3% |
| 2024 | $1.70B | +40.5% |
| 2023 | $1.21B | +25.6% |
| 2022 | $961.20M | +7.4% |
| 2021 | $894.80M | +21.1% |
| 2020 | $738.70M | +0.0% |
| 2019 | $738.40M | +10.3% |
| 2018 | $669.20M | -5.1% |
| 2017 | $705.10M | -31.1% |
| 2016 | $1.02B | +23.0% |
| 2015 | $831.80M | +109.2% |
| 2014 | $397.70M | +39.9% |
| 2013 | $284.30M | +78.4% |
| 2012 | $159.40M | -5.1% |
| 2011 | $168.04M | -33.4% |
| 2010 | $252.16M | +151.3% |
| 2009 | $100.35M | -22.5% |
| 2008 | $129.45M | -7.1% |
| 2007 | $139.32M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.34B | -13.8% | -15.9% |
| June 30, 2025 | $1.59B | +17.5% | -16.1% |
| March 31, 2025 | $1.90B | +51.8% | +11.9% |
| December 31, 2024 | $1.70B | +40.5% | +9.2% |
| September 30, 2024 | $1.55B | +40.3% | +14.6% |
| June 30, 2024 | $1.36B | +27.0% | +8.3% |
| March 31, 2024 | $1.25B | +7.6% | +3.6% |
| December 31, 2023 | $1.21B | +25.6% | +9.0% |
- UNITED THERAPEUTICS Corp showed a decrease of -8.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2007–2025 period, UNITED THERAPEUTICS Corp’s cash and equivalents has grown by 1017.6% (from $139.32 million to $1.56 billion).
- The most recent figure is from UNITED THERAPEUTICS Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: